Literature DB >> 17721739

Disseminated invasive aspergillosis with cerebral involvement successfully treated with caspofungin and voriconazole.

C Gubler1, S M Wildi, A Imhof, M Schneemann, B Müllhaupt.   

Abstract

We describe a case of cerebral aspergillosis which was successfully treated with a combination of caspofungin and voriconazole. The patient remains in remission 18 months after stopping antifungal treatment. We discuss primary and salvage therapy of invasive aspergillosis with focus on cerebral involvement. Since historical data showed a fatal outcome in most cases, amphotericin B does not cross the blood brain barrier while voriconazole does, we chose a combination of voriconazole plus caspofungin as primary therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17721739     DOI: 10.1007/s15010-007-6165-1

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  5 in total

1.  The efficacy of voriconazole in the treatment of 192 fungal central nervous system infections: a retrospective analysis.

Authors:  S Schwartz; A Reisman; P F Troke
Journal:  Infection       Date:  2011-04-22       Impact factor: 3.553

2.  Combined therapy of voriconazole and anidulafungin in murine infections by Aspergillus flavus.

Authors:  Enrique Calvo; F Javier Pastor; Valentina Salas; Emilio Mayayo; Josep Guarro
Journal:  Mycopathologia       Date:  2011-12-04       Impact factor: 2.574

3.  Antifungal activity of antifungal drugs, as well as drug combinations against Exophiala dermatitidis.

Authors:  Yi Sun; Wei Liu; Zhe Wan; Xiaohong Wang; Ruoyu Li
Journal:  Mycopathologia       Date:  2010-08-29       Impact factor: 2.574

4.  Post-transplant aspergillosis and the role of combined neurosurgical and antifungal therapies under belatacept immunosuppression.

Authors:  Ekkehard M Kasper; Jiri Bartek; Scott Johnson; Burkhard S Kasper; Martha Pavlakis; Michael Wong
Journal:  Surg Neurol Int       Date:  2011-06-09

5.  High weekly doses of liposomal amphotericin B as secondary prophylaxis after cerebral aspergillosis in a paediatric patient.

Authors:  Pierluigi Brazzola; Mario R Rossi
Journal:  Med Mycol Case Rep       Date:  2013-11-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.